Literature DB >> 33148662

Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells.

Fangyuan Chen1,2, Kai Ding1,3, Nolan Priedigkeit1,4, Ashuvinee Elangovan1,5, Kevin M Levine1,6,7, Neil Carleton1,6, Laura Savariau1,8, Jennifer M Atkinson1, Steffi Oesterreich1,5, Adrian V Lee9,5.   

Abstract

Invasive lobular breast carcinoma (ILC), one of the major breast cancer histologic subtypes, exhibits unique features compared with the well-studied ductal cancer subtype (IDC). The pathognomonic feature of ILC is loss of E-cadherin, mainly caused by inactivating mutations, but the contribution of this genetic alteration to ILC-specific molecular characteristics remains largely understudied. To profile these features transcriptionally, we conducted single-cell RNA sequencing on a panel of IDC and ILC cell lines, and an IDC cell line (T47D) with CRISPR-Cas9-mediated E-cadherin knockout (KO). Inspection of intracell line heterogeneity illustrated genetically and transcriptionally distinct subpopulations in multiple cell lines and highlighted rare populations of MCF7 cells highly expressing an apoptosis-related signature, positively correlated with a preadaptation signature to estrogen deprivation. Investigation of E-cadherin KO-induced alterations showed transcriptomic membranous systems remodeling, elevated resemblance to ILCs in regulon activation, and increased sensitivity to IFNγ-mediated growth inhibition via activation of IRF1. This study reveals single-cell transcriptional heterogeneity in breast cancer cell lines and provides a resource to identify drivers of cancer progression and drug resistance. SIGNIFICANCE: This study represents a key step towards understanding heterogeneity in cancer cell lines and the role of E-cadherin depletion in contributing to the molecular features of invasive lobular breast carcinoma. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33148662      PMCID: PMC7856056          DOI: 10.1158/0008-5472.CAN-20-0696

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  51 in total

1.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.

Authors:  Anoop P Patel; Itay Tirosh; John J Trombetta; Alex K Shalek; Shawn M Gillespie; Hiroaki Wakimoto; Daniel P Cahill; Brian V Nahed; William T Curry; Robert L Martuza; David N Louis; Orit Rozenblatt-Rosen; Mario L Suvà; Aviv Regev; Bradley E Bernstein
Journal:  Science       Date:  2014-06-12       Impact factor: 47.728

2.  SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma.

Authors:  Emily A Bossart; Nilgun Tasdemir; Matthew J Sikora; Amir Bahreini; Kevin M Levine; Jian Chen; Ahmed Basudan; Britta M Jacobsen; Timothy F Burns; Steffi Oesterreich
Journal:  Breast Cancer Res Treat       Date:  2019-02-23       Impact factor: 4.872

Review 3.  Tumour heterogeneity and resistance to cancer therapies.

Authors:  Ibiayi Dagogo-Jack; Alice T Shaw
Journal:  Nat Rev Clin Oncol       Date:  2017-11-08       Impact factor: 66.675

4.  Generalizing RNA velocity to transient cell states through dynamical modeling.

Authors:  Volker Bergen; Marius Lange; Stefan Peidli; F Alexander Wolf; Fabian J Theis
Journal:  Nat Biotechnol       Date:  2020-08-03       Impact factor: 54.908

5.  g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update).

Authors:  Uku Raudvere; Liis Kolberg; Ivan Kuzmin; Tambet Arak; Priit Adler; Hedi Peterson; Jaak Vilo
Journal:  Nucleic Acids Res       Date:  2019-07-02       Impact factor: 16.971

6.  E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines.

Authors:  M Lombaerts; T van Wezel; K Philippo; J W F Dierssen; R M E Zimmerman; J Oosting; R van Eijk; P H Eilers; B van de Water; C J Cornelisse; A-M Cleton-Jansen
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

7.  WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.

Authors:  Matthew J Sikora; Britta M Jacobsen; Kevin Levine; Jian Chen; Nancy E Davidson; Adrian V Lee; Caroline M Alexander; Steffi Oesterreich
Journal:  Breast Cancer Res       Date:  2016-09-20       Impact factor: 6.466

8.  Punctuated copy number evolution and clonal stasis in triple-negative breast cancer.

Authors:  Ruli Gao; Alexander Davis; Thomas O McDonald; Emi Sei; Xiuqing Shi; Yong Wang; Pei-Ching Tsai; Anna Casasent; Jill Waters; Hong Zhang; Funda Meric-Bernstam; Franziska Michor; Nicholas E Navin
Journal:  Nat Genet       Date:  2016-08-15       Impact factor: 38.330

9.  RNA velocity of single cells.

Authors:  Gioele La Manno; Ruslan Soldatov; Amit Zeisel; Emelie Braun; Hannah Hochgerner; Viktor Petukhov; Katja Lidschreiber; Maria E Kastriti; Peter Lönnerberg; Alessandro Furlan; Jean Fan; Lars E Borm; Zehua Liu; David van Bruggen; Jimin Guo; Xiaoling He; Roger Barker; Erik Sundström; Gonçalo Castelo-Branco; Patrick Cramer; Igor Adameyko; Sten Linnarsson; Peter V Kharchenko
Journal:  Nature       Date:  2018-08-08       Impact factor: 49.962

10.  E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer.

Authors:  Katy Teo; Laura Gómez-Cuadrado; Milou Tenhagen; Adam Byron; Max Rätze; Miranda van Amersfoort; Jojanneke Renes; Eric Strengman; Amit Mandoli; Abhishek A Singh; Joost H Martens; Hendrik G Stunnenberg; Paul J van Diest; Valerie G Brunton; Patrick W B Derksen
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

View more
  8 in total

1.  Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers.

Authors:  Ambily Sivadas; Victor C Kok; Ka-Lok Ng
Journal:  Breast Cancer Res Treat       Date:  2022-03-29       Impact factor: 4.872

2.  Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma.

Authors:  Ashuvinee Elangovan; Jagmohan Hooda; Laura Savariau; Susrutha Puthanmadhomnarayanan; Megan E Yates; Jian Chen; Daniel D Brown; Priscilla F McAuliffe; Steffi Oesterreich; Jennifer M Atkinson; Adrian V Lee
Journal:  Mol Cancer Res       Date:  2022-09-02       Impact factor: 6.333

Review 3.  Beyond Genetics: Metastasis as an Adaptive Response in Breast Cancer.

Authors:  Federica Ruscitto; Niccolò Roda; Chiara Priami; Enrica Migliaccio; Pier Giuseppe Pelicci
Journal:  Int J Mol Sci       Date:  2022-06-03       Impact factor: 6.208

4.  Inferring Cell Subtypes and LncRNA Function by a Cell-Specific CeRNA Network in Breast Cancer.

Authors:  Xin Chen; Jing Xu; Feng Zeng; Chao Yang; Weijun Sun; Tao Yu; Haokun Zhang; Yan Li
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

Review 5.  Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.

Authors:  George Sflomos; Koen Schipper; Thijs Koorman; Amanda Fitzpatrick; Steffi Oesterreich; Adrian V Lee; Jos Jonkers; Valerie G Brunton; Matthias Christgen; Clare Isacke; Patrick W B Derksen; Cathrin Brisken
Journal:  Cancers (Basel)       Date:  2021-10-27       Impact factor: 6.639

Review 6.  Subclonal heterogeneity and evolution in breast cancer.

Authors:  Ioanna Mavrommati; Flora Johnson; Gloria V Echeverria; Rachael Natrajan
Journal:  NPJ Breast Cancer       Date:  2021-12-21

7.  Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cells.

Authors:  Svetlana E Semina; Purab Pal; Nidhi S Kansara; Rosemary J Huggins; Elaine T Alarid; Geoffrey L Greene; Jonna Frasor
Journal:  Breast Cancer Res       Date:  2022-03-09       Impact factor: 6.466

8.  Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas.

Authors:  Sanghoon Lee; Hatice Ulku Osmanbeyoglu
Journal:  Breast Cancer Res       Date:  2022-07-29       Impact factor: 8.408

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.